[Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].
Oxidative stress may play a critical role in the pathogenesis of endothelial dysfunction in patients with diabetes or hypertension. An angiotensin II type 1 receptor(AT1) antagonist candesartan is now a widely used antihypertesive drug, and AT1 activation is a predominant source of oxidative stress. We studied the effect of a 12-week treatment of candesartan(4-12 mg-day) on oxidative stress markers [lipid peroxidation(LPO), malondialdehyde-modified LDL(MDA-LDL), 8-epi-PGF2 alpha, and the generation of superoxide anion by monocytes(CLA-DCL)] in 30 type 2 diabetic patients with hypertension (> 140/85 mmHg). Both MDA-LDL and CLA-DCL were significantly decreased, although the others were not changed. These data suggest that candesartan clinically improves oxidant stress, probably lowering the generation of superoxide anion from blood monocytes.
Sato
Noriyuki
N
Department of Endocrinology and Metabolism, Dokkyo University School of Medicine.
Kase
Hiroyuki
H
Kato
Tetsuya
T
Kasai
Kikuo
K
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects; D044140:Receptor, Angiotensin, Type 1; D013481:Superoxides / Q000097:blood; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D013481:Superoxides; C081643:candesartan